For immediate release
17 December 2018
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Appointment of Non-Executive Directors
Alliance Pharma plc (AIM: APH), the international specialty pharmaceutical company, announces the appointment of two independent Non-Executive Directors, Jo Le Couilliard and Richard Jones, who bring further international business experience and capital markets expertise to the Board. Jo and Richard, who both have substantial pharmaceutical and healthcare experience gained at listed companies, will join the Board on 1 January 2019.
As an executive, Jo Le Couilliard served a total of almost 20 years at GlaxoSmithKline ("GSK"), leaving in June 2018 to focus on non-executive roles. Her recent positions at GSK have included Senior Vice President and Area Head, Asia Pacific, a role in which she was responsible for GSK's sales and marketing in Australia, New Zealand, Korea, Taiwan and Southeast Asia. Jo, who qualified as an accountant at PwC, is currently a non-executive director of the UK-listed healthcare companies Cello Health plc and Circassia Pharmaceuticals plc.
Richard Jones has extensive capital markets, growth company and board experience. Richard is currently the Chief Financial Officer of Mereo BioPharma Group plc, an AIM-listed clinical stage biopharmaceutical company focused on rare diseases before which he was Chief Financial Officer of AIM-listed Shield Therapeutics plc. Prior to these positions, Richard, who qualified as an accountant at PwC, worked in investment banking for a total of 12 years focusing predominantly on the healthcare sector.
David Cook, Alliance Pharma's Chairman, commented: "I am delighted to welcome Jo and Richard to Alliance's Board. They bring a huge breadth of relevant and varied experience to Alliance. Jo's extensive experience at GSK included a senior sales and marketing position in Asia Pacific, which represents Alliance's fastest growing region. Richard, from his work as an investment banker and as a financial executive, brings a depth of relevant capital markets experience. I look forward to their contribution to the Company's ongoing development into a leading international healthcare business."
The following information is disclosed pursuant to Schedule Two, paragraph (g), of the AIM Rules for Companies.
Joanna Susan Le Couilliard, 55 years of age, has been a director or partner of the following companies during the five years preceding the date of this announcement.
Current directorships Past directorships
Cello Health plc GlaxoSmithKline Pte Ltd
Circassia Pharmaceuticals plc Glaxo Wellcome Manufacturing Pte Ltd
General Healthcare Group Ltd
Duke NUS Medical School
Richard Crispin Morgan Jones, 52 years of age, has been a director or partner of the following companies during the five years preceding the date of this announcement.
Mereo BioPharma Group plc
Shield Therapeutics PLC
Mereo BioPharma 1 Limited
Shield TX (UK) LTD
Mereo BioPharma 2 Limited
Shield TX (Switzerland) AG
Mereo BioPharma 3 Limited
Shield TX GmbH
Mereo BioPharma 4 Limited
Shield Holdings AG
Mereo BioPharma Ireland Limited
Iron Therapeutics Holdings AG
Mereo US Holdings Inc
Iron Therapeutics Switzerland AG
Mereo MereoCo Inc
Phosphate Therapeutics Ltd
Krysto Pharma Ltd
Wolverleigh Consultants Limited
There are no further disclosures to be made pursuant to Schedule Two, paragraph (g), of the AIM Rules for Companies in respect of the appointments of Jo Le Couilliard and Richard Jones.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Wills
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / David Herring
Notes to editors:
Alliance Pharma plc is an international specialty pharmaceutical company.
Headquartered in Chippenham, UK, Alliance commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.